Abstract Approximately 1 in 14 men and women during their lifetime will be diagnosed with lung cancer, which is the leading cause of cancer-related mortality in the world. As of January 1, 2008, there were about 373,500 men and women living with lung cancer in the United States. Fewer than 60,000 of these are estimated to be alive by January 2013, reflecting a poor overall 5-year relative survival rate of under 16 %. With metastatic cancer, the overall 5-year survival is meager 4 %. On the other hand, the overall five-year survival is over 50 % when the cancer is still in the localized stage. However, unfortunately, more than half of cases of lung cancer are diagnosed at an advanced stage Howlader et al. (2010) . Cancer metastasis, the single most critical prognostic factor, is still poorly understood and a highly complex phenomenon. The most common sites of lung cancer metastasis are the lymph nodes, liver, adrenals, brain and bones. The gastrointestinal (GI) tract is an exceptionally rare site of metastasis; with only a handful of cases reported in the literature Centeno et al. (Lung Cancer, 18: 101-105, 1997); Hirasaki et al. (World J Gastroenterol, 14: 5481-5483, 2008); Carr and Boulos (Br J Surg, 83: 647, 1996); Otera et al. (Eur Respir Rev, 19: 248-252, 2010); Antler et al. (Cancer, 49: 170-172, 1982 We report three cases of non-small cell (squamous cell) lung cancer with GI tract metastasis-two in the colon and one in the jejunum. Then we present a review of literature exploring various theories of metastasis, as an attempt to understand the reason of preferential tumor metastasis.
thickening of the proximal sigmoid colon with stranding of the surrounding peritoneum with an SUV of 19.4. There was also a hypermetabolic 2.5×1.6 cm mesenteric lymph node mass in the left lower quadrant of the abdomen with an SUV of 9.2. [ Figure 2a -b] A near obstructing mass in the left colon that was impassable on colonoscopy was found. He then underwent laparoscopic segmental colon resection and end-colostomy 3 months after the lung cancer diagnosis. Grossly, there is a 5 cm centrally necrotic mass, occupying the submucosa extending into the pericolonic adipose tissue with a relative sparing of the overlying colonic mucosa. Histologically, the tumor shows squamous differentiation with immunoprofile consistent with SCC (CK5/6+, CK7+, p63+, CK20-, CDX-2-). Based on the growth pattern, histology and immunohistochemical profile the lesion most likely represented metastatic disease from pulmonary SCC.
His post-operative course was complicated by multiple abdominal abscesses requiring pelvic drains and acute respiratory failure secondary to pneumonia, requiring intubation. Due to a worsening clinical course despite aggressive ICU care, his family eventually opted for hospice care. He passed away less than 4 months after the initial lung cancer diagnosis.
Case II
This is a 60 year old white obese man; former smoker (100 pack-years) with a history of Hepatitis C related compensated Child's A cirrhosis, treated with approximately 12 weeks of antiviral therapy several years earlier. He was admitted with progressively worsening exertional dyspnea over 2 years, without any fever, cough or pain. He had decreased appetite, some fatigue and unspecified amount of weight loss. Review of systems was negative. His laboratory analysis was unremarkable with WBC of 7.7 (3.8-10.6×10 9 /L) (81 % granulocytes, 9.7 % lymphocytes and 8.8 % monocytes), hemoglobin 14.3 (12.9-16.6 g/dL), MCV 95.7 (82.6-72.4 fL), platelets 163 (156-379×10 9 /L), AST 42 Fig. 1 Microscopically, the tumor in the colon and jejunum shows squamous differentiation with submucosal growth (a , g , j ). The immunohistochemical profile is consistent with squamous cell carcinoma (p63 positive -b, f, h, k and CDX-2 negative -c, i, l) (10-42 IU/L), ALT 83 (10-60 IU/L), alkaline phosphatase 94 (42-121 IU/L), total bilirubin 0.6 (0.2-1 mg/dL), albumin 3.5 (3.2-5.5 mg/dL), calcium 8.9 (8.5-10.5 mg/dL), sodium 138 (135-143 mmol/L), potassium 4.3 (3.6-5 mmol/L), BUN 6 (6-20 mg/dL) and creatinine 0.9 (0.5-1.2 mg/dL). A chest X-ray showed a new 5 cm density within the left upper lobe. A CT scan of the chest revealed a 7.7×4.8×4.6 cm axillary segment of the left upper lobe mass, along with abnormal lymphadenopathy involving the left hilum, prevascular and left lower paratracheal regions. CT guided biopsy confirmed a SCC (CK5/6+, p63+, CK7 weak+, TTF-1-, Mucicarmine-). [ Figure 1d -i] A PET-CT scan demonstrated a hypermetabolic bulky mass within the apicoposterior segment of the left upper lobe, which extended inferomedially up to the left hilar region. No metastases were noted. He was deemed to be poor surgical candidate due to reduced forced vital capacity (FVC) of 49 % and other comorbidities. For the same reason, no mediastinoscopy was performed.
He completed concurrent chemo-radiation therapy followed by consolidation Carboplatin and Paclitaxel for 2 cycles. A follow-up PET-CT scan 7 months after the initial diagnosis showed no evidence of disease. Three months later, a PET-CT scan showed marked interval progression of the left apical lung malignancy and a new focal area of prominent metabolic uptake in the transverse colon with ill-defined wall thickening with a maximum SUV of 4.7. [ Figure 2c -d] He underwent completed stereotactic body radiation therapy × 5 fractions to the left upper lobe mass. A repeat CT scan 3 months later showed interval increase in the distal transverse colon/splenic flexure mass which measured 3.8×3.8×3.3 cm lesion compared to 2.4×2.4 cm on the prior PET-CT. There was no associated bowel obstruction. There was a slight decrease in the left apical mass measuring 3.7×3.2 cm, as compared to 3.9×3.6 cm in the previous PET-CT. One month later, subsequent colonoscopy showed a 3 cm submucosal mass in the transverse colon. The pathology showed SCC (p63+, CK5/6+, CK20-, CDX-2-). The cytomorphology and immunohistochemical features of this carcinoma were similar to lung fine needle aspiration biopsy and thus consistent with metastatic SCC. Of note, his CEA level was normal.
Afterward, he received 3 cycles chemotherapy with gemcitabine and carboplatin. A follow-up CT scan 4 months later showed increased size of the left upper lobe mass, which was approximately 6.5×4.6 cm, abutting the aortic arch and associated with worsening narrowing of the left upper lobe bronchus. The left hilar mass had also increased in size with central necrosis, along with moderate left pleural effusion and lymphangitic spread of the disease. The soft tissue mass in the transverse colon had also progressed, now invading the left rectus abdominis muscle and measuring 8.9×5.5 cm. Given generalized worsening of the disease and rapidly deteriorating functional status, he declined to pursue any further treatment and opted for home hospice care and died 3 months later.
Case III
A 79 year old white man, former heavy smoker with multiple co-morbidities including atrial fibrillation, hypertension, congestive heart failure, chronic kidney disease, alcoholic cirrhosis status-post peritoneovenous shunt, was admitted to the hospital with acute abdominal pain, delirium and atrial fibrillation with rapid ventricular rate. He was unable to provide further history due to delirium. Except for a lactate level of 6 (0.5-1.5 mMol/ L) and hemoglobin of 9.8 (12.9-16.6 g/dL), rest of his laboratory panel was unremarkable; with a WBC count of 7.4 (3.8-10.6×10 Post-operatively, he developed acute hypoxemic respiratory failure requiring intubation. A CT scan of the chest showed left hilar and mediastinal mass, collapse of the left upper lobe due to obstruction of the upper lobe bronchus, nodular air space disease in the left lower lobe which could represent a metastatic disease and patchy airspace disease in the posterior aspect of the left lower lobe consistent with pneumonia and bilateral pleural effusions. His ICU course was complicated by acute on chronic kidney injury, sepsis secondary to peritonitis, multiloculated abdominal abscesses and sigmoid colitis. His family decided on hospice care, which was consistent with the patient's wishes. Therefore, no biopsy of the lung mass was performed. Based on the pathology and radiological findings, the most likely final diagnosis was primary SCC of the lung with metastasis to the jejunum causing perforation. He died within a month after the surgery.
Discussion
More than half of cases of lung cancer are diagnosed when it is already metastatic [1] . Only a few cases of lung cancer metastasizing to the GI tract are reported in the literature [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Some of the common sites for lung cancer metastasis include thoracic lymph nodes (46-85 %), pleura (14-46 %), liver (38-58 %), brain (14-45 %), adrenals (36-64 %), bones (21-41 %), contralateral lung and kidneys (13-43 %) . Other less commonly involved sites include abdominal lymph nodes, spleen, pancreas, heart, pericardium and skin [13] . An autopsy series examining 124 patients with metastatic non-small lung cancer (NSCLC) found the involvement of abdominal lymph nodes (17 %) and esophagus/stomach (10 %), but no small or large bowel metastases were noted [13] . A separate autopsy series of 423 patients found an overall 14 % (58 cases) involvement of the GI tract from metastatic lung cancer. Out of these, a majority (46 %) were secondary to the direct esophageal extension, while the small and large bowel was involved in only 6 % of the cases [6] .
The rarity of GI involvement is further emphasized in a prospective study involving 350 patients with NSCLC, which assessed the incidence of solitary extra-pulmonary lesions detected by PET-CT [18 F] fluorodeoxyglucose (FDG) uptake. A total of 21 % solitary lesions were detected, more than half (54 %) of which were related to lung cancer metastasis, while the rest were either second malignancies or benign lesions. The sites of solitary extra-pulmonary metastasis from lung cancer included bone (41 %), brain (19 %), liver (19 %), adrenal gland (16 %) and abdominal lymph nodes (5 %). No GI metastases were detected [14] . The addition of PET to CT scan has been a very valuable tool in detecting these metastases. In patients with clinical stage III disease, PET scanning detects extrathoracic metastases in approximately 25 % of patients [8] . Prior to the use of PET imaging it would have been very difficult to detect small GI metastasis with CT scan.
Our three cases of lung carcinoma with biopsy proven GI metastases is a rare occurrence for one institution. All of them had SCC histology and all of them died within a short period of time after diagnosis.
Lung cancer with GI metastasis is reported to have poor prognosis with mean survival of only 4-8 weeks [9] , but it is unclear if GI metastasis has poorer prognosis as compared to other sites of metastasis. There is no literature explaining the possible cause of the rarity of GI metastasis from lung carcinoma. Why lung cancer metastasizes to some organs and spares others may be partially explained by our current understanding of the basic pathobiology of metastatic process in general, which is summarized below.
Theories of Lung Cancer Metastasis

Seed and soil hypothesis
Metastasis is the process of actual seeding of tumor cells into the target organs. This was first described by Paget [15] in 1880s in his "seed and soil hypothesis." He suggested that the tumor cells (seeds) have an affinity for certain organ microenvironment (soil) which offers specific growth enhancing factors; and that the successful seeding occurs only when the seed and soil are compatible. In contrast, James Ewing (the father of "Ewing's Sarcoma") in 1928 suggested that metastasis rather occurred primarily through the anatomic mechanisms-occurring at the site of first tumor cell contact in the circulatory bed of an organ [16] . However, this does not explain the finding of remote metastases without the involvement of proximal organs.
Role of genetics
The role of genetics came into highlight in the later quarter of the twentieth century, when Nowell (1976) [17] proposed that the tumor cells that metastasize are genetically unstable as compared to non-metastatic cells, that sequential accumulation of somatic alterations occur as tumor progresses, and that there is a "genetic variability within the original clone allowing sequential selection of more aggressive sublines". Fidler and Kripke [18] demonstrated the metastatic heterogeneity of tumor cells within a same primary parent tumor. They showed that the different clones of tumor cells from the same primary tumor injected intravenously in mice with B16 melanoma had different potentials to form pulmonary metastasis, suggesting that "the parent tumor is heterogeneous and that highly metastatic tumor cell variants preexist in the parental population."
Over the past 40 years, a vast body of literature has shown that in order to successfully form clinically detectable metastases, a cancer cell within a primary tumor must accumulate an array of genetic and molecular changes that enable it to complete all of the steps of the metastatic process-the metastatic cascade.
These steps include escaping from the primary tumor, intravasation into local vasculature or lymphatics, survival within the vasculature or lymphatics, extravasation, and finally proliferation within a secondary microenvironment (termed metastatic colonization). Disseminated tumor cells can also undergo evolution in parallel with those within the primary tumor; this important concept should be incorporated into future models of metastasis progression. As these steps became more clearly defined at the molecular level, it became evident that the discrete metastatic processes can be regulated independently of tumor growth. This prompted the hypothesis that genes, which specifically regulate metastasis formation, for example metastasis-suppressor genes [MSGs], could be identified and used to better understand the metastatic process. To date, there have been more than 20 bona fide MSGs identified in a myriad of tumor types, affecting a breadth of cellular processes. MSG, could impact the care of cancer patients, from improving prognostic and predictive capabilities to the development of new treatment options [19] .
The presence of several metastasis suppression genes is now well documented [20] -such as in melanoma (NM23, chromosomes 6 and 1), prostate (NM23, 7q21-22, 8p21-p12, 10q23, 11p11.2-13, 12qcen-q13, 16q24.2, 17p12-11.2), breast (NM23, Chromosome 6 and 11q13.1-13.2) and colon (NM23, 11p11.2) cancers. MSGs in lung cancer include NM23 (multifunction kinase), PEBP1 (inhibits nuclear factor κβ and RAF/MEK/ERK signaling), RECK (GPI-anchored glycoprotein inhibits matrix metalloproteinases), CTGF (extracellular matrix turnover, integrin binding), and KAI1 (inhibits cell migration and invasion) [20] .
It is also known that the tumor cells may lay dormant at one site without forming metastasis, but develop metastasis at other sites. Goldberg et al. showed that the chromosome-6 hybrid human melanoma cells injected intravenously into mice did not form macro-metastasis in the lungs. Two months later, the melanoma cells were able to be isolated from lung and grow in culture; and were able to form metastasis when injected in the skin [21] . Thus, genetics may very well play a crucial role in organ specific metastasis. Several polymorphic genes have now been identified suggesting genetic susceptibility as one of the underlying etiologies of metastasis [22, 23] . Metastasis suppression genes have also been identified [24] . What remains unclear is whether genetic susceptibility of tumor cells leads to preferential organ metastasis.
In addition, inter-cellular genetic communication of tumor cells via exosomal miRNA can trigger signal transduction which can modulate cell behavior and promote tumor growth. For instance, the micro RNA miR-143 is known to have low level of expression in various tumors including NSCLC, colorectal, prostate, pancreatic, cervical, gastric cancer and leukemia (reviewed in ref [25] ) and upregulation of miR-143 in NSCLC cell lines has an inhibitory effect on tumor migration and invasion [25] .
Local extension, vascular invasion and lymphatic metastasis
Lung cancer spreads via local extension, vascular invasion or lymphatic involvement [26] . It is well known that the metastatic process is highly intricate but an inefficient process, with only a small percentage of tumor cells actually capable of forming successful metastasis. In-vivo studies suggest that a vast majority of tumor cells injected in the circulation are trapped in lung circulation or liver sinusoids. Although many of these are able to survive and extravasate into the organ tissues, yet only a few are actually able to form metastases and develop into macroscopic tumors [27] [28] [29] [30] . Few cells capable of forming metastasis are capable of doing so for unknown reason.
Extracellular matrix, mesenchymal cell and adhesion molecule
Cancer cells have to overcome several barriers generated by natural body defenses. One of the earliest steps in metastasis includes detachment from the extracellular matrix (ECM) and invasion of the circulatory system. Many theories have been proposed to explain the detachment of these epithelial cells, which are otherwise so tightly bound to each other with the help of tight-junctions, gap-junctions and desmosomes. One of these is the epithelial-to-mesenchymal transition (EMT) model [31] , which suggests that the epithelial cells transform into highly mobile mesenchymal cells. It is also proposed by the fusion theory of metastasis [32] , that the tumor cells are actually capable of fusing with the leucocytes which helps them with the process of EMT and subsequent metastasis.
Once in the circulation (blood or lymphatic), tumor cells are clever enough to evade the apoptotic processes [33] as they are poorly immunogenic as well as immunosuppressive [34] , can down-regulate the antigens and lymphocytes responses to cytokines [35] , and secrete certain cytokines that helps them with the immune suppression. They are also capable of downregulating adhesion molecules such as E-cadherin [36] , which helps them with the invasion. Further, overexpression of certain transcription factors such as Snail, Slug, and E47 in the epithelial tumor cells [37] not only help them with the EMT process but also suppress E-cadherin expression, which in turn, has been shown to be highly correlated with metastasis [38] .
Theory of Angiogenesis
Angiogenesis is crucial for tumor growth and metastasis. The angiogenic switch refers to a phenotypic change that occurs early in a tumor's development that is necessary for growth beyond 2-3 mm in size. Hypoxia is the trigger for many of the mechanisms by which a tumor induces angiogenesis. For example, hypoxia induces the expression of hypoxia-inducible factor (HIF-1), which in turn up-regulates vascular endothelial growth factor (VEGF) [39] . There are several proangiogenic properties of chemokines, which are produced by tumor cells and infiltrating stromal cells in lung cancer and other malignancies. These are largely produced by NF-kB transcriptional activation, and represent an alternative pathway for the angiogenic switch. Other important factors that promote tumor angiogenesis either directly or indirectly include basic fibroblast growth factor (bFGF), macrophage migration inhibitory factor (MIF), angiopoietin 1, and epidermal growth factor(EGF) [40] . NSLC neoangiogenesis, as measured by microvessel density (MVD), and tumor expression of VEGF are poor prognostic factors for survival.
Tumors from human lung cancer specimens express a pattern of angiogenic factors that suggests activation of one dominant factor, or "angiogenic signature" in each tumor. This angiogenic signature depends, in part, on the presence of mutant K-ras. While the presence of activating K-ras mutations does not exclusively predict the predominance of chemokine expression in the angiogenic mechanism of a tumor, there was a trend toward increased chemokine expression in K-ras mutant tumors compared with K-ras wild-type tumors. The presence of mutant K-ras did decrease the likelihood of VEGF being highly expressed in these tumors. These data support a paradigm of tumor angiogenesis being a characteristic that is both variable from tumor to tumor, and adaptable within a given tumor [39] .
Microvessel count (MC) or density, which represents a measure of tumour angiogenesis, has been associated with metastatic spread in cutaneous, mammary, prostatic, head and neck, and early-stage lung cancer. Fontanini [41] studied the role of tumor angiogenesis as a prognostic indicator was examined in 253 primary NSCLC patients. MC related closely with hilar and mediastinal nodal metastasis and tumors with high MC (> 25 vessels/field) were significantly associated with increased death risk.
Role of Blood Cells and Coagulation System
The coagulation system [42] , especially tissue factor and thrombin are also involved in tumor proliferation and metastasis via the action of latter on protease activated receptor-1 (PAR-1) [43] . Increased expression of PAR-1 is postulated to promote metastasis of malignant melanoma [44, 45] , breast [46, 47] , colon [48] and prostate cancer [49, 50] .
The role of several blood cells in metastasis, including endothelial cells, platelets, lymphocytes, macrophages, mast cells, fibroblasts and bone marrow-derived progenitor cells in metastasis is also well defined in literature [42, 51] . Platelets, because of their close interaction with the coagulation system, have a distinct and multifactorial contribution to tumor growth, angiogenesis as well as metastasis. (Reviewed in ref [51, 52] ) Platelets modulate vascular permeability potentially assisting with tumor extravasation; and have various factors that promote angiogenesis-including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), epidermal growth factor (EGF), cytokines (IL-1β and IL-8) and proteases (MMP2 and MMP9). Because of the vital role in metastasis, some of these factors, such as the pro-angiogenic platelet factor-4 (PF-4) and an anti-angiogenic factor CTAP-III (connective tissue activating peptide III) have been proposed as potential biomarkers for tumor growth [53] . In addition, it is hypothesized that platelets along with fibrin "protect" the tumor cells from immune clearance by coating them [54] on route during hematogenous spread. (Reviewed in [51, 52] )
Other blood cells, such as the Natural Kill (NK)-cells may determine organ specific permissiveness leading to the establishment of a metastatic niche [55, 56] . This was elaborated in a study showing that melanoma cells injected intravenously in mouse models readily metastasized to lungs which had higher content of mature NK-cells, but not to the liver which was dominated by the immature population of NK-cells. Further, depletion of NK-cells led to significant hepatic metastasis [55] . The immature NK-cells have been postulated to prevent tumor growth and metastasis via their perforin-dependent cytotoxic mechanism.
Metastatic SCC
Researchers have examined gene expression profiles of SCC of the lung to address three major areas of concern: (1) to account for the histologic heterogeneity of NSCLC and to differentiate SCC from other subtypes, (2) to identify prognostic factors specific to SCC, and (3) to aid in distinguishing primary pulmonary SCC from metastatic head and neck SCC (HNSCC) [57] .
There are two different clusters of gene encoding protein in lung SCC. Larson and colleagues compared gene expression profiles of node-negative SCC tumors (N0) with signatures obtained from tumors with ipsilateral hilar or peribronchial nodal involvement (N1) via direct nodal invasion and with signatures obtained from N1 tumors with regional lymph node metastases via lymphatics. He found that N1 tumors with direct lymphatic invasion were similar to N0 tumors and distinct from N1 tumors with lymphatic spread, both in terms of molecular features and prognosis [58] .
There is no effective immunohistochemistry panel to determine the origin of SCC. Because primary SCC of the lung must be distinguished from metastatic HNSCC, this poses a diagnostic dilemma in patients with a history of HNSCC who subsequently develop a pulmonary nodule. Vachani and colleagues used a training set of 18 HNSCC and 10 pulmonary SCCs to develop a 10-gene profile to distinguish these two tumor types. This classifier was validated on 122 subjects from previously published independent datasets, with 96 % accuracy. Using real-time PCR, they correctly classified 12 independent samples as either of head and neck or pulmonary origin [59] .
Conclusion
Our three cases of SCC of the lung with GI metastasis represent a very rare occurrence-the reason for which is uncertain. Lung cancer metastasis represents the final step of a complex sequence composed of invasion (loss of cell-cell adhesion, increased cell motility, and basement membrane degradation), vascular intravasation and extravasation, establishment of a metastatic niche and angiogenesis. The GI tract may be a less attractive environment as compared to other organs such as adrenal glands, liver, bones and brain. It is known that squamous histology tends to be more aggressive and the prognosis is worse as compared to other types of lung carcinoma. This is true since metastatic adenocarcinoma has better treatment options (erlotinib for EGFR mutated cells and crizotinib for ALK mutated cells) and this may translated into better survival. A better understanding of the pathobiology and genomics of SCC is warranted for a better targeted therapy in the near future.
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